Compass Therapeutics annual debt-to-equity ratio
2020
2021
2022
2023
2024
2025
Compass Therapeutics Debt-to-Equity Ratio Growth & History (CMPX)
Compass Therapeutics's debt-to-equity ratio was 0.05 for fiscal 2025.
View full Compass Therapeutics company overviewCompass Therapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.05 | −0.00 | −5.71% |
| 2024 | 2024-12-31 | 0.05 | 0.04 | +354.04% |
| 2023 | 2023-12-31 | 0.01 | −0.00 | −27.80% |
| 2022 | 2022-12-31 | 0.02 | −0.01 | −43.93% |
| 2021 | 2021-12-31 | 0.03 | −0.20 | −87.67% |
| 2020 · Dec 31 | 2020-12-31 | 0.23 | — | — |
Compass Therapeutics quarterly debt-to-equity ratio
Q4.19
Q1.21
Q2.21
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.06 | −0.05 | −45.40% |
| Q1 2026 | 2026-03-31 | 0.05 | −0.01 | −9.26% |
| Q4 2025 | 2025-12-31 | 0.05 | −0.00 | −5.71% |
| Q3 2025 | 2025-09-30 | 0.05 | −0.00 | −5.63% |
| Q2 2025 | 2025-06-30 | 0.11 | 0.10 | +1326.91% |
| Q1 2025 | 2025-03-31 | 0.06 | 0.05 | +543.16% |
| Q4 2024 | 2024-12-31 | 0.05 | 0.04 | +354.04% |
| Q3 2024 | 2024-09-30 | 0.05 | 0.04 | +289.26% |
| Q2 2024 | 2024-06-30 | 0.01 | −0.01 | −46.54% |
| Q1 2024 | 2024-03-31 | 0.01 | −0.01 | −40.32% |
| Q4 2023 | 2023-12-31 | 0.01 | −0.00 | −27.80% |
| Q3 2023 | 2023-09-30 | 0.01 | −0.01 | −53.95% |
| Q2 2023 | 2023-06-30 | 0.01 | −0.01 | −49.42% |
| Q1 2023 | 2023-03-31 | 0.02 | −0.01 | −46.18% |
| Q4 2022 | 2022-12-31 | 0.02 | −0.01 | −43.93% |
| Q3 2022 | 2022-09-30 | 0.03 | −0.31 | −91.87% |
| Q2 2022 | 2022-06-30 | 0.03 | −0.33 | −92.25% |
| Q1 2022 | 2022-03-31 | 0.03 | −0.34 | −92.42% |
| Q4 2021 | 2021-12-31 | 0.03 | −0.20 | −87.67% |
| Q3 2021 | 2021-09-30 | 0.34 | 0.10 | +44.07% |
| Q2 2021 · Jun 30 | 2021-06-30 | 0.36 | 0.11 | +45.11% |
| Q1 2021 · Mar 31 | 2021-03-31 | 0.37 | — | — |
| Q4 2020 · Dec 31 | 2020-12-31 | 0.23 | −1.09 | −82.29% |
| Q2 2021 · Sep 30 | 2020-09-30 | 0.24 | — | — |
| Q1 2021 · Jun 30 | 2020-06-30 | 0.24 | — | — |
| Q4 2019 · Dec 31 | 2019-12-31 | 1.32 | — | — |
Compass Therapeutics debt-to-equity ratio trends
Over the last five fiscal years, Compass Therapeutics's debt-to-equity ratio decreased from 0.23 to 0.05, a change of −0.18. The latest reported quarter, Q2 2026, shows 0.06.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Compass Therapeutics source filings ↗